YMAB Stock Overview
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.
Y-mAbs Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$14.42|
|52 Week High||US$29.53|
|52 Week Low||US$6.50|
|1 Month Change||-10.32%|
|3 Month Change||-6.00%|
|1 Year Change||-50.80%|
|3 Year Change||-44.02%|
|5 Year Change||n/a|
|Change since IPO||-39.92%|
Recent News & Updates
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
The latest analyst coverage could presage a bad day for Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ), with the analysts...
|YMAB||US Biotechs||US Market|
Return vs Industry: YMAB underperformed the US Biotechs industry which returned -25.8% over the past year.
Return vs Market: YMAB underperformed the US Market which returned -21.5% over the past year.
|YMAB Average Weekly Movement||11.1%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: YMAB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: YMAB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Y-mAbs Therapeutics Fundamentals Summary
|YMAB fundamental statistics|
Is YMAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YMAB income statement (TTM)|
|Cost of Revenue||US$5.08m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.09|
|Net Profit Margin||-338.68%|
How did YMAB perform over the long term?See historical performance and comparison
Is YMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YMAB?
Other financial metrics that can be useful for relative valuation.
|What is YMAB's n/a Ratio?|
Price to Sales Ratio vs Peers
How does YMAB's PS Ratio compare to its peers?
|YMAB PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
IDYA IDEAYA Biosciences
AUPH Aurinia Pharmaceuticals
YMAB Y-mAbs Therapeutics
Price-To-Sales vs Peers: YMAB is expensive based on its Price-To-Sales Ratio (15.8x) compared to the peer average (13.1x).
Price to Earnings Ratio vs Industry
How does YMAB's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: YMAB is expensive based on its Price-To-Sales Ratio (15.8x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is YMAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||15.8x|
|Fair PS Ratio||22.9x|
Price-To-Sales vs Fair Ratio: YMAB is good value based on its Price-To-Sales Ratio (15.8x) compared to the estimated Fair Price-To-Sales Ratio (22.9x).
Share Price vs Fair Value
What is the Fair Price of YMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate YMAB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate YMAB's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Y-mAbs Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YMAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YMAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YMAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YMAB's revenue (45.9% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: YMAB's revenue (45.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YMAB is forecast to be unprofitable in 3 years.
Discover growth companies
How has Y-mAbs Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YMAB is currently unprofitable.
Growing Profit Margin: YMAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: YMAB is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: YMAB has a negative Return on Equity (-102.7%), as it is currently unprofitable.
Discover strong past performing companies
How is Y-mAbs Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: YMAB's short term assets ($153.9M) exceed its short term liabilities ($29.5M).
Long Term Liabilities: YMAB's short term assets ($153.9M) exceed its long term liabilities ($4.3M).
Debt to Equity History and Analysis
Debt Level: YMAB is debt free.
Reducing Debt: YMAB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YMAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: YMAB has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 29.7% each year.
Discover healthy companies
What is Y-mAbs Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Y-mAbs Therapeutics Dividend Yield vs Market|
|Company (Y-mAbs Therapeutics)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Y-mAbs Therapeutics)||0%|
Notable Dividend: Unable to evaluate YMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if YMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YMAB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as YMAB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Gad (52 yo)
Mr. Thomas Gad founded Y-mAbs Therapeutics, Inc. in April 2015 and serves as its Interim Chief Executive Officer since April 22, 2022, serves as its President, Head of Business Development & Strategy and D...
CEO Compensation Analysis
|Thomas Gad's Compensation vs Y-mAbs Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$500k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$4m||US$471k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$3m||US$440k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$3m||US$395k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$598k||US$350k|
Compensation vs Market: Thomas's total compensation ($USD1.87M) is below average for companies of similar size in the US market ($USD4.14M).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
Experienced Management: YMAB's management team is considered experienced (4.8 years average tenure).
Experienced Board: YMAB's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|09 Feb 22||SellUS$2,021,188||Thomas Gad||Individual||281,170||US$7.59|
|04 Feb 22||SellUS$1,055,558||Thomas Gad||Individual||136,164||US$7.90|
|24 Jan 22||SellUS$936,412||Thomas Gad||Individual||88,055||US$10.96|
|21 Jan 22||SellUS$2,033,105||Thomas Gad||Individual||183,085||US$11.35|
|19 Jan 22||SellUS$760,676||Thomas Gad||Individual||69,814||US$11.46|
|07 Dec 21||SellUS$901,074||Thomas Gad||Individual||54,000||US$17.58|
|30 Nov 21||SellUS$746,571||Thomas Gad||Individual||43,607||US$17.16|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Y-mAbs Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Y-mAbs Therapeutics, Inc.
- Ticker: YMAB
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$630.436m
- Shares outstanding: 43.72m
- Website: https://www.ymabs.com
Number of Employees
- Y-mAbs Therapeutics, Inc.
- 230 Park Avenue
- Suite 3350
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|YMAB||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 2018|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.